12:43 PM EST - Nova Mentis Life Science Corp : Announces that the company has produced 1.5 mg psilocybin microdose capsules, produced according to defined manufacturing processes and product specifications as outlined in chemistry, manufacturing and controls published guidelines. "NOVA has accomplished a breakthrough in its autism spectrum disorder clinical research program with the production of GMP grade psilocybin microdose capsules," stated Jacqueline McConnell, NOVA's Chief Operating Officer. "NOVA is excited to initiate the availability of the 1.5 mg psilocybin capsules to doctors, clinics and pharmaceutical companies in Canada for its potential therapeutic use in non-ASD clinical trials, including diabetes, heart disease, epileptic conditions and post-traumatic stress disorder. NOVA and KGK Science Inc. are available to assist in the creation and submission of future clinical trial applications to Health Canada for review." Nova Mentis Life Science Corp
shares C.NOVA are trading unchanged at $0.03.
